Express Pharma

CHMP recommends EU approval of Actemra/RoActemra to treat patients with severe COVID-19

Actemra/RoActemra reduced the risk of death in patients with severe COVID-19, as evidenced by a review of four phase-III studies. The European Commission is expected to make a final decision regarding approval in the near future